MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "1-Methyl-4-phenylpyridinium (MPP+)"

  • 2025 International Congress

    Pharmacological PGC-1α Activation Mitigates Dopaminergic Degeneration in Parkinson’s Disease Via Regulating Mitochondrial Homeostasis

    J. Kaur, S. Naqvi (Lucknow, India)

    Objective: To understand the role of mitochondrial function in improving the outcomes of Parkinson’s disease (PD) via pharmacologically activating PGC-1α by its synthetic activator ZLN005.…
  • 2025 International Congress

    Establishing a Timeline of Non-Motor and Motor Symptoms Progression in Parkinson’s Disease Using a Sub-Chronic MPTP Mouse Model

    M. Chopra, A. Sekar, R. Hussain, L. Diwakar (Bengaluru, India)

    Objective: Parkinson’s disease (PD) mouse model using 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was explored for pathological mechanisms driving non-motor symptoms (NMS). Aim was to map the behavioural changes…
  • 2025 International Congress

    Protective effects of Hesperidin loaded polymeric nanoparticles on the progression of MPTP Induced Parkinson’s disease via targeting GPR43/NLRP3 signaling pathway: in vitro and in vivo studies

    M. Singh (Prayagraj, India)

    Objective: Emphasizing the G protein-coupled receptor 43 (GPR43) and the NLRP3 signaling pathway in both in vitro and in vivo models, this work studies the…
  • 2025 International Congress

    Investigating the Neuroprotective Potential of Mushroom Extracts in Parkinson’s Disease In Vitro Models

    SEO. Seo, FAZ. Dustov (Tashkent, Uzbekistan)

    Objective: This study aims to evaluate the neuroprotective potential of various mushroom extracts in in vitro models of PD. Background: Parkinson’s disease (PD) is a…
  • 2025 International Congress

    Dietary Caffeic Acid Exhibits Neuroprotective and Neuromodulatory Effects in a Parkinsonian Rat Model by Mitigating Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis

    A. Singh (Prayagraj, India)

    Objective: This study investigated the neuroprotective and neuromodulatory effects of dietary caffeic acid (CA) in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonian rat model Background: Parkinson’s disease (PD)…
  • 2024 International Congress

    SARS-CoV-2 induced neurodegeneration in oxidative stress and genetic models of Parkinson’s Disease

    D. Chatterjee, T. Rodriguez, K. Crowther, M. Byrne, R. Smeyne (Philadelphia, USA)

    Objective: Given similarities in systemic responses after infection with SARS-CoV-2 to those reported after the 1918 pandemic, we investigated whether SARS-CoV-2 could elicit a similar…
  • 2024 International Congress

    The Neuroprotective Effects of Rolipram, a Selective Phosphodiesterase IV Inhibitor, on Parkinson’s Disease in Rat Models: A Pharmacological Exploration in both In vivo and In vitro Settings

    R. Kumar, A. Kanojia (Darbhanga, India)

    Objective: Our research sought to unravel the pharmacological effects and mechanisms of action of Rolipram through both in vivo and in vitro experimentation in models…
  • 2024 International Congress

    Design, synthesis and pharmacological evaluation of 16-pyridylmethylene derivatives of steroidal oximes as antiparkinsonian agents in MPTP-injected mice.

    R. Singh, R. Bansal (Chandigarh, India)

    Objective: The objective of the present study is focused on the design and synthesis of 16-pyridyl methylene derivatives of steroidal oximes and further their pharmacological…
  • 2024 International Congress

    Differences in Molecular and Ultrastructural profiles of astroglia and microglia in substantia nigra of two different mice strains in normal aging and experimental Parkinsonism

    P. Alladi, A. Abhilash, U. Bharti, R. Santhosh Kumar, M. Philip, B. Chandrasekhar Sagar (Bangalore, India)

    Objective: To examine whether the variable sensitivity of dopaminergic neurons of the substantia nigra pars compacta -SNpc- in C57BL/6J and CD-1 mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/ MPTP…
  • 2024 International Congress

    Impact of sub-acute MPTP exposure on the cerebellum in adult male Balb/c mice

    F. Sulaimon, R. Ibiyeye, R. Adeniyi, Y. Jimoh, M. Awodola, T. Adeoye, M. Shehu (Ilorin, Nigeria)

    Objective: The objective of the study was to investigate the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration on the cerebellum of adult male Balb/c mice Background: Parkinson’s…
  • 1
  • 2
  • 3
  • …
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • #28970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley